Endometrial Cancer

1. Overview

Endometrial cancer is a malignancy arising from the endometrial lining of the uterus. It represents the most common gynaecological malignancy in developed countries and the fourth most common cancer in women overall. [1]

"The Cancer of Unopposed Estrogen"

This aphorism encapsulates the fundamental pathophysiology of Type I endometrial cancer, where prolonged exposure to estrogen without adequate progesterone opposition drives malignant transformation.

Key Epidemiological Facts

• Incidence: Rising globally, particularly in high-income countries

  • "UK: 9,700 new cases annually (2020 data)"
  • "USA: 66,000 new cases annually"
  • Increasing incidence attributable to obesity epidemic [1,2]

• Age Distribution:

  • "Peak incidence: 60-70 years"
  • "Mean age at diagnosis: 63 years"
  • 5% occur in women less than 40 years (often associated with hereditary syndromes or PCOS)
  • "Pre-menopausal cases: Usually associated with anovulation or obesity [3]"

• Survival Statistics:

  • "Overall 5-year survival: 81%"
  • "Stage-dependent outcomes (FIGO 2009):"
    • Stage I: 90-95%
    • Stage II: 70-80%
    • Stage III: 50-60%
    • Stage IV: 15-20%
  • Excellent prognosis compared to ovarian/cervical cancer due to early symptomatic presentation [4]

• Risk by Demographics:

  • "Lifetime risk: 1 in 36 women (2.8%)"
  • Higher in white/European populations compared to Asian populations
  • Protective effect observed in multiparous women

Global Trends

The incidence of endometrial cancer is rising in parallel with:

• Obesity epidemic (strongest modifiable risk factor)
• Increasing life expectancy
• Earlier menarche and later menopause (prolonged estrogen exposure)
• Declining rates of hysterectomy for benign disease [2]

---

2. Molecular Classification and Pathophysiology

Traditional Dualistic Model

Historically, endometrial cancer was classified into two types:

Type I: Endometrioid Adenocarcinoma (80%)

• Pathogenesis: Estrogen-dependent
• Precursor: Endometrial hyperplasia with atypia
• Risk Factors: Obesity, PCOS, nulliparity, tamoxifen
• Molecular Features: PTEN mutations (50-80%), PIK3CA mutations, microsatellite instability
• Histology: Glandular architecture resembling normal endometrium
• Grade: Usually Grade 1-2
• Prognosis: Favorable (5-year survival 85-90%)

Type II: Non-Endometrioid Carcinoma (20%)

• Subtypes: Serous, clear cell, carcinosarcoma
• Pathogenesis: Estrogen-independent
• Precursor: Endometrial intraepithelial carcinoma (EIC) or atrophic endometrium
• Molecular Features: TP53 mutations (> 90%), HER2/neu overexpression
• Histology: Papillary architecture (serous), hobnail cells (clear cell)
• Behavior: Highly aggressive, early extrauterine spread
• Prognosis: Poor (5-year survival 50-55%)

Modern Molecular Classification (TCGA/ProMisE)

The Cancer Genome Atlas (TCGA) project revolutionized endometrial cancer classification by identifying four distinct molecular subtypes with prognostic and therapeutic implications: [5]

1. POLE-Ultramutated (7-10%)

• Molecular Feature: Pathogenic mutations in DNA polymerase epsilon (POLE exonuclease domain)
• Mutational Burden: Extremely high (> 100 mutations/Mb)
• Histology: Often high-grade endometrioid
• Prognosis: Excellent - best survival across all groups
• Clinical Implication: May not require adjuvant therapy even if high-grade
• Therapeutic Relevance: Potential target for immunotherapy

2. MMR-Deficient/MSI-High (25-30%)

• Molecular Feature: Mismatch repair (MMR) deficiency → microsatellite instability (MSI)
• Mechanisms:
  • "Sporadic: MLH1 promoter hypermethylation (most common)"
  • "Hereditary: Lynch syndrome (germline mutations in MLH1, MSH2, MSH6, PMS2)"
• Histology: Endometrioid, often with tumor-infiltrating lymphocytes
• Prognosis: Intermediate
• Therapeutic Relevance: Highly responsive to immune checkpoint inhibitors (pembrolizumab, dostarlimab) [6]
• Clinical Action: All cases require Lynch syndrome evaluation

3. p53-Abnormal (10-15%)

• Molecular Feature: TP53 mutations
• Histology: Predominantly serous, also grade 3 endometrioid
• IHC Pattern: Complete absence (null pattern) or strong diffuse overexpression
• Behavior: Aggressive, high recurrence rates
• Prognosis: Poorest survival
• Spread Pattern: Peritoneal dissemination similar to ovarian cancer
• Therapeutic Approach: Requires aggressive adjuvant therapy

4. NSMP (No Specific Molecular Profile) (40-50%)

• Molecular Feature: None of the above (POLE wild-type, MMR-proficient, p53 wild-type)
• Histology: Low-grade endometrioid
• Molecular Alterations: PTEN, PIK3CA, ARID1A, CTNNB1 mutations
• Prognosis: Intermediate-favorable
• Management: Standard surgical-pathological staging directs therapy

Clinical Integration of Molecular Classification

The 2023 ESGO/ESTRO/ESP guidelines now incorporate molecular classification into risk stratification and treatment decisions: [7]

Risk Groups Based on Integration:

• Low Risk: POLE-mutated (any stage/grade)
• Intermediate Risk: NSMP, Stage IA, Grade 1-2, LVSI-negative
• High-Intermediate Risk: NSMP/MMRd, Stage IB, Grade 1-2, or Stage IA Grade 3
• High Risk: p53-abnormal, Stage II-III, or substantial LVSI
• Advanced/Metastatic: Stage IV

---

3. Risk Factors

The "Unopposed Estrogen" Hypothesis

Endometrial cancer pathogenesis is fundamentally driven by the balance between estrogen (proliferative) and progesterone (secretory/protective).

Mechanism:

Estrogen → Endometrial proliferation
                ↓
         No progesterone opposition
                ↓
         Persistent proliferation
                ↓
         Simple hyperplasia → Complex hyperplasia → Atypia → Adenocarcinoma

Major Risk Factors (Mnemonic: ENDOMET)

E - Elderly Age

• Incidence increases sharply after menopause
• Peak incidence 60-70 years
• Relative risk increases 10-fold from age 40 to 60

N - Nulliparity

• RR: 2-3 compared to parous women [8]
• Mechanism: Pregnancy provides 9 months of progesterone protection
• Each full-term pregnancy reduces risk by ~10%
• Infertility itself (anovulation) also increases risk independently

D - Diabetes Mellitus

• RR: 2.1 (95% CI 1.7-2.6) [9]
• Independent risk factor even after adjusting for obesity
• Mechanisms:
  • Hyperinsulinemia → IGF-1 pathway activation
  • Advanced glycation end-products
  • Chronic inflammation
• Type 2 diabetes confers greater risk than Type 1

O - Obesity

• THE STRONGEST MODIFIABLE RISK FACTOR
• Risk increases proportionally with BMI: [10]
  • "BMI 25-29.9: RR 2.0"
  • "BMI 30-34.9: RR 3.6"
  • "BMI ≥35: RR 7.1"
• Mechanism: Adipose tissue contains aromatase enzyme
  • Converts adrenal androgens (androstenedione) → estrone (a weak estrogen)
  • Post-menopausal adipose tissue becomes primary estrogen source
• Weight loss reduces risk proportionally

M - Menstrual Irregularity / PCOS

• Chronic anovulation → unopposed estrogen
• Polycystic Ovarian Syndrome (PCOS): RR 2.7 [11]
• Late menopause (> 55 years): RR 2.4
• Early menarche (less than 12 years): RR 1.5
• Each year of menstruation adds cumulative estrogen exposure

E - Estrogen Monotherapy (HRT)

• Unopposed estrogen HRT: RR 5-10 [12]
• Duration-dependent risk:
  • less than 1 year: minimal risk
  • 5-10 years: RR 5-6

  • 10 years: RR 10+

• CRITICAL: Adding cyclical or continuous progesterone eliminates excess risk
• Tibolone (synthetic steroid): neutral or slight risk reduction

T - Tamoxifen

• Selective Estrogen Receptor Modulator (SERM)
• Anti-estrogenic in breast tissue
• Estrogenic in endometrium
• RR: 2-3 after 5 years of use [13]
• Absolute risk increase: 2-3 cases per 1000 women-years
• Mechanism: Agonist activity at endometrial ER
• Increased risk of polyps, hyperplasia, and cancer (including serous type)
• Recommendation: Annual gynaecological assessment; investigate any bleeding promptly

Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer)

• Germline mutations: MLH1, MSH2, MSH6, PMS2
• Lifetime risk of endometrial cancer: 40-60% (exceeds colorectal cancer risk in women) [14]
• Mean age at diagnosis: 48 years (15 years younger than sporadic cases)
• Often presents as sentinel cancer before colorectal malignancy
• Amsterdam II Criteria and Revised Bethesda Guidelines for screening
• Recommendation: Annual endometrial surveillance from age 30-35, or risk-reducing hysterectomy after childbearing

Protective Factors

Understanding protective factors guides prevention strategies:

Combined Oral Contraceptive Pill (COCP)

• RR: 0.5 (50% risk reduction) [15]
• Mechanism: Progestogenic component induces secretory transformation
• Protection increases with duration:
  • 4 years: 30% reduction
  • 8 years: 40% reduction
  • 12 years: 50% reduction
• Persistence: Protection lasts 15-20 years after discontinuation
• One of the most important non-contraceptive benefits

Multiparity

• Each pregnancy: ~10% risk reduction
• ≥5 pregnancies: 60% reduction compared to nulliparous
• Mechanism: Prolonged progesterone exposure during pregnancy

Smoking

• RR: 0.71 (controversial protective effect) [16]
• Mechanism: Anti-estrogenic effects (increased metabolism, earlier menopause)
• NOT RECOMMENDED as prevention strategy (overwhelming harms)

Physical Activity

• Regular exercise: 20-30% risk reduction
• Mechanism: Weight control, insulin sensitivity improvement, reduced inflammation

---

4. Clinical Presentation

Cardinal Symptom: Post-Menopausal Bleeding (PMB)

Definition: Any vaginal bleeding occurring > 12 months after the last menstrual period.

Clinical Maxim: "PMB is cancer until proven otherwise"

Prevalence of Cancer in PMB:

• Overall: 5-10% of women with PMB have endometrial cancer [17]
• Risk stratified by endometrial thickness:
  • ET less than 4 mm: less than 1% cancer risk
  • ET 5-10 mm: 5-10% cancer risk
  • ET > 10 mm: 20-30% cancer risk

90% of endometrial cancers present with PMB, accounting for excellent overall survival.

Pre-Menopausal Presentation

Less common, but should raise suspicion in:

• Intermenstrual bleeding (IMB) - especially > 40-45 years
• Menorrhagia resistant to medical management
• Post-coital bleeding (less specific)
• Irregular heavy periods in PCOS patients

Other Symptoms (Less Common)

• Watery/serosanguinous discharge (10-15%)
  • "Pink" or blood-tinged discharge
  • May precede frank bleeding
• Pyometra (infected collection in uterine cavity)
  • Purulent discharge, pelvic pain, fever
  • Occurs with cervical stenosis
• Pelvic pain (10%)
  • Late symptom suggesting advanced disease
  • Hematometra (blood collection) from cervical obstruction
• Abdominal distension
  • Ascites in advanced/serous subtypes
• Weight loss, fatigue (advanced disease)

Asymptomatic Presentation

• Incidental finding on imaging (thickened endometrium)
• Detected during evaluation for Lynch syndrome
• Screening in high-risk populations (controversial)

---

5. Diagnostic Pathway

Two-Week Wait (2WW) Referral Criteria (NICE NG12)

Urgent referral (seen within 2 weeks) for suspected gynaecological cancer:

• Post-menopausal bleeding (age > 55 years) - DIRECT REFERRAL
• Visible hematuria + raised CA125 + pelvic mass
• Pelvic mass palpated on examination (unless clearly fibroids)

Step 1: Transvaginal Ultrasound Scan (TVUSS)

First-line investigation for PMB in primary and secondary care.

Technique

• Bladder emptied prior to scan
• 5-7.5 MHz transvaginal probe
• Measure endometrial thickness (ET) in sagittal plane
• Double layer measurement: Anterior + posterior endometrium

Interpretation Thresholds (Post-Menopausal)

Caveats:

• Threshold does NOT apply to pre-menopausal women (thicker endometrium physiological)
• Any bleeding on tamoxifen → hysteroscopy regardless of ET (tamoxifen causes thickness)
• Polyps require histological assessment regardless of size
• Focal thickening or heterogeneity mandates biopsy

TVUSS Diagnostic Performance

• Sensitivity: 96% (excellent rule-out at less than 4mm)
• Specificity: 61%
• NPV: 99% (at less than 4mm threshold)

Step 2: Endometrial Sampling

Gold standard: Histological diagnosis

A. Pipelle Biopsy (Outpatient)

Technique:

• Thin flexible plastic catheter (3mm diameter)
• Inserted through cervix into uterine cavity
• Suction created by withdrawing inner piston
• Rotated 360° to sample endometrium
• Can be performed in GP surgery or outpatient clinic
• No anesthesia required (mild cramping common)

Diagnostic Performance:

• Sensitivity: 81-99% for cancer detection [18]
• Lower sensitivity for focal lesions (polyps)
• Adequate sample obtained in 90-95% of cases

Advantages:

• Outpatient procedure
• Low cost
• Well-tolerated
• Immediate results (within 2 weeks)

Limitations:

• Cervical stenosis (10-15% of post-menopausal women) → inadequate sample
• Sampling error for polyps or focal disease
• Patient discomfort (vasovagal episodes rare)

Failed Pipelle Biopsy:

• Stenosed cervix
• Endometrial atrophy (insufficient cells)
• Management: Proceed to hysteroscopy under anesthesia

B. Hysteroscopy + Dilatation & Curettage (D&C)

Gold standard for diagnosis

Indications:

• Failed pipelle biopsy
• ET > 10mm
• Focal lesions (polyps, fibroids)
• Tamoxifen users
• High clinical suspicion despite negative pipelle
• Recurrent PMB after negative pipelle

Technique:

• Usually performed under general anesthesia (can be outpatient with local anesthesia)
• Cervix dilated using Hegar dilators
• Hysteroscope (rigid or flexible) inserted into cavity
• Direct visualization of endometrial cavity
• Targeted biopsy of suspicious areas
• Curettage of entire cavity

Advantages:

• Direct visualization (identifies polyps, fibroids, lesions)
• Targeted biopsies
• Therapeutic (can remove polyps simultaneously)
• Highest diagnostic accuracy

Complications (rare):

• Uterine perforation (1:1000)
• Hemorrhage
• Infection
• Fluid overload (if using glycine for distension)

---

6. Staging Investigations

Once histological diagnosis confirmed, staging workup determines extent of disease and guides treatment.

FIGO Staging System (2009)

Endometrial cancer uses surgical-pathological staging (unlike cervical cancer which is clinical).

Key Changes from 2009 FIGO:

• Stage IA and IB now defined solely by depth of myometrial invasion
• Grade no longer part of staging (but critical for risk stratification)
• Positive peritoneal cytology no longer upstages (removed in 2009)

Imaging for Staging

MRI Pelvis (Gold Standard for Local Staging)

Indications: All cases of endometrial cancer

Information Provided:

• Myometrial invasion depth: Most critical parameter
  • less than 50% vs ≥50% (Stage IA vs IB)
  • "Accuracy: 85-90%"
• Cervical stromal invasion (Stage II)
• Extrauterine spread: Serosa, adnexa, parametrium
• Lymph node assessment: Pelvic and para-aortic
  • "Criteria: Size > 1cm, round shape, necrosis"
  • Moderate sensitivity (50-70%)
• Bladder/rectal invasion (Stage IVA)

Sequences:

• T2-weighted: Anatomical detail (junctional zone)
• T1-weighted with contrast: Tumor enhancement, myometrial invasion
• Diffusion-weighted imaging (DWI): Tumor detection, nodal assessment

Limitations:

• Cannot reliably detect lymphovascular space invasion (LVSI)
• Microscopic peritoneal disease not visible

CT Chest/Abdomen/Pelvis

Indications:

• High-grade histology (Grade 3 endometrioid, serous, clear cell, carcinosarcoma)
• Suspected advanced disease (Stage III-IV)
• Deep myometrial invasion on MRI
• Suspicious lymphadenopathy

Purpose:

• Detect distant metastases:
  • Lung (hematogenous spread)
  • Liver
  • Peritoneal disease
  • Retroperitoneal lymphadenopathy

Limitations:

• Poor assessment of myometrial invasion (MRI superior)

PET-CT

Indications (limited):

• Recurrent disease detection
• Assessment of distant metastases in high-risk subtypes
• Not routine for primary staging

Tumor Markers

CA125:

• Elevated in ~25% of endometrial cancers (higher in serous/clear cell)
• Correlates with advanced disease and peritoneal involvement
• Prognostic value: Elevated pre-treatment CA125 predicts worse outcomes
• Surveillance: Rising CA125 may indicate recurrence
• Not sensitive/specific for diagnosis (also elevated in benign conditions)

HE4 (Human Epididymis Protein 4):

• Emerging marker
• May complement CA125 in non-endometrioid histologies

---

7. Histopathology

Histological Subtypes

Endometrioid Adenocarcinoma (75-80%)

Microscopic Features:

• Glandular architecture resembling proliferative endometrium
• Back-to-back glands with reduced intervening stroma
• Stratified columnar epithelium with nuclear atypia
• Villoglandular, secretory, or ciliated variants

Grading (FIGO):

• Grade 1: ≤5% solid (non-glandular) growth
• Grade 2: 6-50% solid growth
• Grade 3: > 50% solid growth

Variants:

• Villoglandular: Papillary with fibrovascular cores (good prognosis)
• Secretory: Subnuclear vacuoles (favorable)
• Ciliated cell: Ciliated epithelium (rare, favorable)

Serous Adenocarcinoma (5-10%)

Microscopic Features:

• Complex papillary architecture
• Marked nuclear atypia (high-grade by definition)
• Psammoma bodies (calcifications) common
• Resembles high-grade serous ovarian carcinoma

Behavior:

• Highly aggressive
• Early transperitoneal spread (even Stage IA has 30% occult extrauterine disease)
• TP53 mutation in > 90%

Clinical Implication:

• Requires comprehensive surgical staging (lymphadenectomy, omentectomy)
• Adjuvant chemotherapy recommended even for early-stage

Clear Cell Carcinoma (3-5%)

Microscopic Features:

• Cells with clear cytoplasm (glycogen-rich)
• Hobnail cells protruding into lumina
• Tubulocystic or solid patterns

Behavior:

• Aggressive
• Poor response to chemotherapy
• Often presents at advanced stage

Carcinosarcoma (Malignant Mixed Müllerian Tumor) (3-5%)

Microscopic Features:

• Biphasic tumor: Malignant epithelial (carcinomatous) + mesenchymal (sarcomatous) components
• Sarcomatous elements: Homologous (endometrial stromal) or heterologous (rhabdomyosarcoma, chondrosarcoma)

Molecular:

• Now classified as metaplastic carcinoma (monoclonal origin)
• TP53 mutations common

Behavior:

• Extremely aggressive
• Highest recurrence rates
• Poor survival (5-year survival ~35%)

Critical Pathological Prognostic Factors

Lymphovascular Space Invasion (LVSI)

Definition: Tumor emboli within endothelial-lined spaces (capillaries, lymphatics)

Prognostic Impact:

• Substantial LVSI: Independent predictor of lymph node metastases and recurrence [19]
• Triples risk of nodal involvement
• Integrated into 2023 FIGO staging and ESGO risk groups

Quantification:

• Focal: less than 3 vessels involved
• Substantial: ≥3 vessels or extensive involvement

Clinical Implication:

• Determines need for adjuvant radiotherapy in early-stage disease

Depth of Myometrial Invasion

Measurement:

• Inner 1/3, middle 1/3, outer 1/3
• less than 50% vs ≥50% (Stage IA vs IB)

Significance:

• Strongest predictor of lymph node metastases
  • less than 50%: 5% LN+ risk
  • ≥50%: 20-25% LN+ risk

Cervical Stromal Invasion

Two Types:

1. Glandular involvement only: Endocervical glands involved (NOT stromal) → Stage I (not II)
2. Stromal invasion: Tumor invades cervical stroma → Stage II

Clinical Implication:

• Alters surgical approach (may require radical hysterectomy)

Lower Uterine Segment (LUS) Involvement

• Predictor of nodal metastases
• Impacts radiotherapy field

---

8. Management

Principles of Treatment

1. Surgery is the cornerstone for early-stage disease
2. Molecular classification increasingly guides adjuvant therapy decisions
3. Minimally invasive approaches (laparoscopic/robotic) preferred when feasible
4. Multidisciplinary team (MDT) discussion essential for all cases

---

Primary Surgical Management

Standard Surgery: Total Hysterectomy + Bilateral Salpingo-Oophorectomy (TH-BSO)

Procedure:

• Total hysterectomy: Removal of uterus + cervix
• Bilateral salpingo-oophorectomy: Removal of both ovaries and fallopian tubes

Rationale for BSO:

• Ovaries are source of estrogen (tumor stimulus)
• 5% risk of ovarian metastases (especially serous/clear cell)
• Fallopian tubes: Site of occult metastases

Surgical Approach:

Evidence:

• LAP2 Trial: Laparoscopic approach non-inferior to laparotomy for oncological outcomes [20]
• LACE Trial: Laparoscopic surgery associated with fewer complications, faster recovery
• Preferred approach: Minimally invasive when feasible

Lymphadenectomy: When and Why?

Controversy: Routine systematic lymphadenectomy vs selective approach

Rationale FOR Lymphadenectomy:

• Accurate staging (identifies Stage IIIC disease)
• Guides adjuvant therapy decisions
• Potential therapeutic benefit (debatable)

Rationale AGAINST Routine Lymphadenectomy:

• MRC ASTEC Trial and Italian Trial: No survival benefit from systematic lymphadenectomy in early-stage disease [21]
• Morbidity: Lymphedema (10-20%), lymphocyst formation, vascular injury

Current Consensus:

• Low-risk disease (Grade 1-2 endometrioid, less than 50% invasion, no LVSI): Lymphadenectomy NOT required
• High-risk disease: Consider lymphadenectomy (or sentinel node mapping)

Sentinel Lymph Node (SLN) Mapping

Technique:

• Injection of tracer (indocyanine green, ICG) into cervix
• Identification of first-draining (sentinel) lymph node(s)
• Selective removal and ultrastaging (serial sectioning + IHC)

Advantages:

• Lower morbidity than full lymphadenectomy
• Higher detection rate of micrometastases (ultrastaging)
• 95% sensitivity for nodal disease [22]

NCCN Algorithm:

• If SLN identified bilaterally → remove SLN only
• If no SLN on one side → side-specific lymphadenectomy

Emerging Standard: SLN mapping replacing routine lymphadenectomy

Omentectomy

Not routine for endometrioid histology

Indications:

• Serous/clear cell carcinoma: High risk of omental metastases
• Visible omental disease
• Intra-abdominal spread suspected

---

Adjuvant Therapy

Decision based on integrated risk stratification:

• Histological type
• Grade
• Stage
• Molecular classification
• LVSI status

Risk-Stratified Adjuvant Therapy (ESGO/ESTRO/ESP 2023 Guidelines) [7]

Vaginal Brachytherapy (VBT)

Technique:

• Radioactive source placed in vaginal cylinder
• Treats vaginal cuff (common site of recurrence)
• Typically 3 fractions of 7 Gy

Advantages:

• Low toxicity
• Excellent local control (vaginal recurrence less than 2%)
• Preserves quality of life

Indications:

• Intermediate-risk disease

External Beam Radiotherapy (EBRT)

Technique:

• Pelvic radiation: 45-50 Gy in 25-28 fractions
• Treats pelvic lymph nodes and parametria

PORTEC-1 and PORTEC-2 Trials: [23]

• EBRT reduces pelvic recurrence (15% → 5%)
• No overall survival benefit (recurrences salvageable with radiotherapy)
• Increased long-term toxicity (bowel, bladder, sexual dysfunction)

Indications:

• High-risk early-stage disease (Stage IB Grade 3, substantial LVSI)
• Stage II-III disease
• p53-abnormal tumors

Chemotherapy

Regimens:

• Carboplatin + Paclitaxel: Standard first-line (every 3 weeks × 6 cycles)
• Alternative: Doxorubicin + Cisplatin (higher toxicity)

PORTEC-3 Trial (High-Risk EC): [24]

• Chemoradiotherapy vs radiotherapy alone
• Improved failure-free survival with chemoRT in high-risk disease
• Particularly beneficial in serous/clear cell histology

Indications:

• Stage III-IV disease
• Serous/clear cell carcinoma (any stage)
• Grade 3 endometrioid with deep invasion

---

Immunotherapy: A Paradigm Shift

Immune Checkpoint Inhibitors in dMMR/MSI-High EC

Mechanism:

• PD-1 inhibitors (pembrolizumab, dostarlimab) block immune checkpoint
• MMR-deficient tumors have high mutational burden → neoantigen presentation → immunogenic

Landmark Trials:

1. KEYNOTE-158 (Pembrolizumab Monotherapy):

   • ORR: 48% in dMMR advanced EC [6]
   • Durable responses (> 12 months)

2. GARNET (Dostarlimab Monotherapy):

   • ORR: 42.3% in dMMR advanced EC
   • FDA approved 2021

3. NRG-GY018 (Pembrolizumab + Chemo vs Chemo):

   • First-line advanced/recurrent EC
   • Improved PFS and OS in dMMR subgroup
   • Benefit also seen in pMMR (less pronounced)

Current Indications:

• dMMR/MSI-high advanced or recurrent EC: Pembrolizumab or dostarlimab (with or without chemotherapy)
• First-line setting: Combination pembrolizumab + carboplatin/paclitaxel

Future Directions:

• Moving into adjuvant setting (ongoing trials)
• Combination strategies (immunotherapy + targeted agents)

---

Fertility-Sparing Treatment

Candidates:

• Young women (less than 40 years) desiring future fertility
• Grade 1 endometrioid adenocarcinoma
• No myometrial invasion (confirmed on MRI)
• No extrauterine disease
• Willing to accept close surveillance

Treatment Protocol:

• High-dose progestogens:
  • Megestrol acetate 160mg daily OR
  • Medroxyprogesterone acetate (Provera) 200-600mg daily OR
  • Levonorgestrel intrauterine system (Mirena coil) ± oral progestogens

Monitoring:

• Repeat biopsy every 3 months
• MRI every 6 months
• Complete response: 50-75% of cases (median 6-9 months)
• Recurrence risk: 30-40% (often within 2 years)

Recommendation:

• After childbearing complete → definitive hysterectomy + BSO

Contraindications:

• Grade 2-3 histology
• Myometrial invasion
• Lynch syndrome (unless very compelling circumstances)

---

Treatment of Recurrent Disease

Patterns of Recurrence:

• Vaginal vault (40%): Most common, often salvageable
• Pelvic (25%)
• Distant (35%): Lung, liver, peritoneum, bone

Management:

Isolated Vaginal Recurrence

• Radiotherapy (if not previously given): 70-80% 5-year survival
• Surgery (exenteration) in select cases

Pelvic Recurrence

• Radiotherapy ± chemotherapy
• Palliative surgery in select cases

Distant Metastases

• Systemic chemotherapy: Carboplatin/paclitaxel
• Immunotherapy: dMMR/MSI-high tumors (pembrolizumab, dostarlimab)
• Hormonal therapy: Progestogens (25% response rate in well-differentiated tumors)
• Targeted therapy:
  • Lenvatinib + pembrolizumab (FDA approved for advanced pMMR EC)
  • HER2-targeted therapy (trastuzumab) for HER2+ tumors (rare)

Prognosis:

• Median survival with recurrent disease: 12-18 months
• Vaginal recurrence: Better outcomes (salvageable)
• Distant recurrence: Poorer prognosis

---

9. Prognosis

Overall Survival by Stage

Prognostic Factors

Favorable:

• POLE-mutated molecular subtype
• Grade 1-2 endometrioid histology
• Age less than 60 years
• Stage IA
• No LVSI
• Diploid DNA content

Unfavorable:

• p53-abnormal molecular subtype
• Serous/clear cell/carcinosarcoma histology
• Age > 70 years
• Deep myometrial invasion
• Lymph node metastases
• Substantial LVSI
• Cervical stromal invasion

---

10. Complications and Sequelae

Surgical Complications

Immediate:

• Hemorrhage (1-2%)
• Ureteric injury (0.5-1%): Higher risk with lateral extension, adhesions
• Bladder injury (0.5%)
• Bowel injury (rare, 0.1%)
• Venous thromboembolism (VTE): 1-2% despite prophylaxis (cancer + surgery + obesity = high risk)

Early Post-Operative:

• Wound infection (2-5%)
• Pelvic hematoma/abscess
• Ileus
• Urinary retention

Late:

• Lymphedema (10-20% after lymphadenectomy): Chronic leg swelling
• Vault prolapse (5%): Vaginal apex descends
• Vaginal cuff dehiscence (rare, less than 1%)

Radiotherapy Complications

Acute (During/Shortly After Treatment):

• Diarrhea
• Cystitis
• Vaginal discharge
• Fatigue
• Skin reactions (perineum)

Late (Months to Years):

• Vaginal stenosis (30-40%): Fibrosis, shortened vagina, dyspareunia
  • "Mitigation: Vaginal dilators, lubricants, topical estrogen"
• Chronic diarrhea/proctitis (10%)
• Bladder dysfunction (5%)
• Small bowel obstruction (1-2%)
• Pelvic fractures (rare, after high-dose RT)

Chemotherapy Toxicity

• Neutropenia (infection risk)
• Peripheral neuropathy (paclitaxel): Permanent in 5-10%
• Alopecia
• Nausea/vomiting
• Fatigue

Psychosocial Impact

• Surgical menopause: Abrupt estrogen withdrawal (hot flashes, mood changes, bone loss, cardiovascular risk)
• Loss of fertility: Grief, identity issues
• Sexual dysfunction: Vaginal dryness, dyspareunia, loss of libido
• Anxiety/depression: Cancer diagnosis, fear of recurrence
• Body image: Weight changes, alopecia, scars

Supportive Care:

• Hormone replacement therapy (HRT): Generally safe in early-stage endometrioid EC (discuss benefits/risks)
• Vaginal estrogen for atrophy
• Psychosexual counseling
• Survivorship programs

---

11. Special Populations

Tamoxifen Users

• Breast cancer survivors on adjuvant tamoxifen
• Increased risk of endometrial cancer (RR 2-3)
• Also increased risk of polyps and hyperplasia
• Any bleeding → urgent hysteroscopy (TVUSS unreliable due to tamoxifen-induced thickening)
• Annual gynaecological review recommended
• Balance risk vs benefit (tamoxifen prevents breast cancer recurrence)

Lynch Syndrome

• 40-60% lifetime risk of endometrial cancer
• Often sentinel cancer (presents before colorectal cancer)
• Younger age at diagnosis (mean 48 years vs 63 years)
• Screening options:
  • Annual endometrial biopsy from age 30-35
  • Annual TVUSS (less sensitive)
• Risk-reducing surgery: Hysterectomy + BSO after childbearing complete
  • Consider at age 40 or when family planning complete
  • Can be combined with prophylactic colectomy if needed

Genetic Counseling:

• All endometrial cancer cases less than 60 years should undergo tumor MMR testing (IHC)
• If dMMR → reflex germline testing for Lynch syndrome

Obesity and Endometrial Cancer

• BMI ≥35: 7-fold increased risk
• Peri-operative challenges:
  • Anesthetic risk
  • Difficult surgical access (laparoscopy technically challenging)
  • Increased VTE risk
  • Higher wound infection rates
• Prehabilitation: Weight loss, exercise, smoking cessation prior to surgery
• VTE prophylaxis: Extended duration (28 days) post-operatively

---

12. Prevention Strategies

Primary Prevention

1. Weight Management:

   • Most important modifiable risk factor
   • Each 5-unit BMI increase → 50% increased risk
   • Weight loss reduces risk

2. Physical Activity:

   • 30 minutes moderate exercise 5×/week
   • 20-30% risk reduction

3. Combined Oral Contraceptive Pill:

   • 50% risk reduction with long-term use (> 10 years)
   • Protection persists 15-20 years after discontinuation

4. Diabetes Control:

   • Metformin may have protective effect (under investigation)

5. Dietary Factors:

   • Plant-based diet, low processed carbohydrates
   • Protective: Fruits, vegetables, fiber
   • Harmful: Red meat, high glycemic index foods

Secondary Prevention (High-Risk Populations)

Lynch Syndrome:

• Risk-reducing hysterectomy + BSO at age 40 or after childbearing
• Annual surveillance if surgery declined

Obesity + PCOS:

• Weight loss
• Metformin (may reduce risk in PCOS)
• Cyclical progestogens or COCP to oppose estrogen

Tamoxifen Users:

• Annual gynaecological assessment
• Low threshold for investigation of bleeding

---

13. Key Clinical Pearls

Exam-Focused Points

1. PMB Pathway:

   • PMB → TVUSS
   • ET less than 4mm → Reassure (but re-investigate if recurs)
   • ET ≥4mm → Endometrial sampling (pipelle or hysteroscopy)

2. Protective Factors:

   • COCP (strongest)
   • Multiparity
   • Smoking (don't recommend!)

3. Lynch Syndrome:

   • Think HNPCC = Colon + Endometrial + Ovarian
   • Endometrial cancer often presents before colorectal cancer in women
   • Screen all EC patients less than 60 years for MMR deficiency

4. Pipelle Biopsy:

   • Can be done in GP/clinic (outpatient)
   • Sensitivity 81-99%
   • If inadequate sample (cervical stenosis) → hysteroscopy under anesthesia

5. Atrophic Vaginitis:

   • Most common cause of PMB (thin friable mucosa)
   • Endometrial cancer is most important cause

6. Molecular Classification:

   • POLE-mutated: Best prognosis (no adjuvant therapy even if high-grade)
   • p53-abnormal: Worst prognosis (aggressive adjuvant therapy)
   • MMR-deficient: Responsive to immunotherapy (pembrolizumab, dostarlimab)

7. Laparoscopic Surgery:

   • Preferred approach when feasible
   • Non-inferior oncological outcomes
   • Faster recovery, fewer complications

---

Common Exam Scenarios

Scenario 1: Classic PMB

• 65-year-old obese woman, diabetic, presents with PMB
• Diagnosis? Endometrial cancer (until proven otherwise)
• First investigation? TVUSS
• If ET 12mm? Endometrial biopsy (pipelle or hysteroscopy)

Scenario 2: Tamoxifen User

• 55-year-old on tamoxifen for breast cancer has spotting
• Management? Urgent referral for hysteroscopy (don't rely on TVUSS)

Scenario 3: Lynch Syndrome Screening

• 48-year-old diagnosed with endometrial cancer, family history of colon cancer
• What to test? Tumor MMR IHC (dMMR suggests Lynch syndrome)
• If dMMR? Offer germline genetic testing, screen for colorectal cancer

Scenario 4: Fertility-Sparing

• 32-year-old nulliparous woman, Grade 1 endometrioid adenocarcinoma, confined to endometrium on MRI
• Option? High-dose progestogens (Mirena + oral provera)
• Monitoring? Biopsy every 3 months
• Ultimate recommendation? Hysterectomy + BSO after childbearing

Scenario 5: Molecular Subtype

• Stage IB Grade 3 endometrioid cancer, POLE-mutated
• Adjuvant therapy? Observation (POLE-mutated has excellent prognosis)

---

14. Patient Explanation

What is endometrial cancer?

"Endometrial cancer is cancer of the lining of the womb. It's the most common cancer affecting the womb, and usually occurs after menopause."

What causes it?

"It's often linked to hormones. The female hormone estrogen causes the womb lining to thicken each month. Normally, another hormone called progesterone balances this out. But if you have too much estrogen for too long—such as from being overweight, because fat tissue makes estrogen—the lining can become too thick and eventually turn cancerous."

What are the symptoms?

"The most common symptom is bleeding after the menopause—any bleeding more than a year after your periods stopped. If you're still having periods, unusually heavy or irregular bleeding could be a sign. The good news is that this bleeding happens early, so we often catch the cancer at an early, curable stage."

How is it diagnosed?

"We start with an ultrasound scan to measure the thickness of the womb lining. If it's thickened, we take a small sample of tissue—either with a thin tube in the clinic (pipelle biopsy) or with a camera inside the womb (hysteroscopy). The tissue is sent to the lab to look for cancer cells."

What is the treatment?

"The main treatment is surgery to remove the womb, ovaries, and fallopian tubes. This is usually done with keyhole surgery (laparoscopy), which means a quicker recovery. Because most women have bleeding early, we often catch the cancer before it's spread, and surgery alone can cure it. Some women may need radiotherapy or chemotherapy afterwards, depending on the type and stage of cancer."

What is the outlook?

"The outlook is generally very good—over 80% of women are cured. If caught early (which it usually is, because of the bleeding symptom), the cure rate is over 90%. Modern treatments, including newer drugs that boost the immune system, are improving outcomes even further."

---

15. Guidelines Summary

RCOG Green-Top Guideline 67 (2016): Management of PMB

Key Recommendations:

• TVUSS first-line investigation for PMB
• ET less than 4mm: Cancer risk less than 1% → reassure (no biopsy)
• ET ≥4mm: Endometrial sampling required
• Recurrent PMB after negative workup: Repeat investigations (hysteroscopy)

ESGO/ESTRO/ESP Guidelines (2023): Endometrial Cancer [7]

Key Updates:

• Molecular classification integration: POLE, MMR, p53, NSMP classification guides treatment
• Risk stratification: Combines histology, stage, molecular profile, LVSI
• Adjuvant therapy:
  • "POLE-mutated: No adjuvant therapy regardless of grade/stage (IA-IB)"
  • p53-abnormal: Aggressive adjuvant chemoradiotherapy
  • "MMR-deficient: Consider immunotherapy (advanced disease)"
• Sentinel lymph node mapping: Preferred over routine lymphadenectomy

NCCN Guidelines (2025): Uterine Neoplasms

Key Points:

• Comprehensive surgical staging for high-risk histologies
• Sentinel lymph node algorithm endorsed
• Immunotherapy (pembrolizumab, dostarlimab) for dMMR/MSI-high advanced/recurrent disease
• Molecular testing recommended for all cases

---

16. Future Directions

Molecular Profiling as Standard of Care

• Universal molecular classification (POLE, MMR, p53, NSMP) increasingly adopted
• Trials underway to de-escalate therapy in POLE-mutated tumors
• Targeted therapies based on molecular alterations (e.g., PIK3CA inhibitors for NSMP tumors)

Immunotherapy Expansion

• Moving into adjuvant setting (KEYNOTE-B21 trial ongoing)
• Combination strategies: Immunotherapy + targeted agents (lenvatinib)
• Biomarker refinement beyond MMR/MSI (tumor mutational burden, PD-L1)

Liquid Biopsies

• Circulating tumor DNA (ctDNA) for:
  • Early detection (high-risk populations)
  • Minimal residual disease monitoring
  • Predicting recurrence
• Potential to avoid invasive surveillance

Artificial Intelligence

• AI-assisted pathology for grading and molecular subtype prediction
• Radiomics: MRI-based deep learning to predict myometrial invasion, LVSI, nodal status

---

17. References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

2. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354-361. doi:10.1093/jnci/djx214

3. Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399(10333):1412-1428. doi:10.1016/S0140-6736(22)00323-3

4. Cancer Research UK. Uterine cancer survival statistics. Accessed January 2026.

5. Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi:10.1038/nature12113

6. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/JCO.19.02105

7. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39. doi:10.1136/ijgc-2020-002230

8. Setiawan VW, Pike MC, Karageorgi S, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol. 2012;176(4):269-278. doi:10.1093/aje/kws129

9. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365-1374. doi:10.1007/s00125-007-0681-5

10. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015;129(7):872-880. doi:10.1016/j.puhe.2015.04.017

11. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748-758. doi:10.1093/humupd/dmu012

12. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304-313. doi:10.1016/0029-7844(94)00383-O

13. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784. doi:10.1016/S0140-6736(11)60993-8

14. Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG, Crosbie EJ. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019;21(10):2167-2180. doi:10.1038/s41436-019-0536-8

15. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27,276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16(9):1061-1070. doi:10.1016/S1470-2045(15)00212-0

16. Zhou B, Yang L, Sun Q, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121(6):501-508. doi:10.1016/j.amjmed.2008.01.044

17. Gredmark T, Kvint S, Havel G, Mattsson LA. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol. 1995;102(2):133-136. doi:10.1111/j.1471-0528.1995.tb09063.x

18. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288(13):1610-1621. doi:10.1001/jama.288.13.1610

19. Versluis MAC, de Jong RA, Plat A, et al. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer. 2015;113(5):786-793. doi:10.1038/bjc.2015.268

20. Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331-5336. doi:10.1200/JCO.2009.22.3248

21. ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125-136. doi:10.1016/S0140-6736(08)61766-3

22. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384-392. doi:10.1016/S1470-2045(17)30068-2

23. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Lancet. 2000;355(9213):1404-1411. doi:10.1016/s0140-6736(00)02139-5

24. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273-1285. doi:10.1016/S1470-2045(19)30395-X